THE REGISTRY OF THE EUROPEAN MANTLE CELL LYMPHOMA NETWORK
INDOLENT MCL (2015) & MOLECULAR MECHANISMS OF RELAPSED MCL (2015)
THE EMCL
Is a pan European collaboration of researchers who joined forces to improve the treatment of
Mantle Cell Lymphoma (MCL). The network unifies clinicians, pathologists, epidemiologists, statisticians and basic researches for this important task. For more information about the EMCL read here
EMCL-REGISTRY
MCL is a rare disease and for various reasons not every question can be addressed in a
clinical trial. Registry data can help to evaluate open questions by collecting real world information about treatments and disease courses. At this time the registry focusses on patients considered to suffer from so called indolent MCL or patients with relapsed disease receiving second line treatment with a novel targeted agent.
EMCL BIOBANK
The Biobank of the EMCL aims to provide a tool to complement clinical data with samples obtained during the disease course.
This is needed to fully understand disease mechanisms which are associated with progression and resistance to current treatments. At this time the EMCL is setting up the requirements to run such a biobank and hopefully we will start soon to collect samples.